The mucosal lining of the bronchus is the most common site of origin for lung carcinoma. The trachea, which lies in the anterior mediastinum, divides into the right and left lungs, and then divides into lobar bronchi for the upper, middle and lower lobes on the right and the upper and lower lobes on the left. The lungs are encased in a membrane called the visceral pleura; a similar membrane called the parietal pleura lines the chest cavity. The potential space between these two membranes is the pleural space.
Lung Histopathology
There are two major histologic types of tumors: small cell (some types of small cell are referred to as oat cell), and non-small cell. Small cell anaplastic carcinoma tends to be disseminated at the time of diagnosis. This is an aggressive and rapidly growing neoplasm. Disease is limited to the thorax at presentation in only 25% of patients. Metastases will be found in regional glands, bone, the central nervous system, and the bone marrow.
Non-small cell lung cancer is a less aggressive disease, but still metastasizes frequently to sites including opposite lung, liver, bone, kidney, mediastinal nodes, pleura, adrenals, and the central nervous system.
Prognostic Factors
Cell type and stage of disease at presentation are important prognostic factors. Additionally, age, sex, albumin and LDH levels, recent weight loss, and performance status at initial presentation have prognostic value in most types of lung cancer.
Treatment

Non-small cell lung cancer
Initial treatment for NSCLC depends upon the stage or resectability of the tumor. Treatment for stage I-II, resectable disease is typically surgery. Patients with stage IIIA disease often receive combined modality therapy (i.e. chemotherapy plus surgery or chemotherapy plus radiation therapy) or radiation alone.
Patients with more advanced disease typically receive chemotherapy.
Small cell lung cancer
Patients with extensive disease are treated with chemotherapy. Patients with limited disease are often treated with a combination of chemotherapy and radiation therapy. Responses are common in small cell carcinoma, but survival benefit is limited. 
T0
No evidence of primary tumor.
Tis Carcinoma in situ.
T1
Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion moreproximal than the lobar bronchus* (i.e., not in main bronchus).
T1a
Tumor ≤ 2 cm in greatest dimension.
T1b
Tumor > 2 cm but ≤ 3 cm in greatest dimension.
T2
Tumor > 3 cm but ≤7 cm or tumor with any of the following features (T2 tumors with these features are classified T2a if ≤ 5 cm)
• Involves main bronchus, 2 cm or more distal to the carina • Invades the visceral pleura (PL1 or PL2)
• Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung
T2a
Tumor > 3 cm but ≤ 5 cm in greatest dimension.
T2b
Tumor > 5 cm but ≤ 7 cm in greatest dimension. 
T3
Tumor > 7 cm that directly invades any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus less than 2 cm distal to the carina but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe.
T4
Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina; separate tumor nodule(s) in a different ipsilateral lobe.
*The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1.
Regional Lymph Nodes (N)
NX
Regional lymph nodes cannot be assessed
N0
No regional lymph node metastasis
N1
Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes involved by direct extension of the primary tumor
N2
Metastasis to ipsilateral mediastinal and/or subcarinal lymph node(s)
N3
Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene or supraclavicular lymph node(s) (See the version 7 of the AJCC Staging Manual for information on regional nodal stations for staging)
Distant Metastasis
MX
Presence of distant metastasis cannot be assessed.
M0
No distant metastasis.
M1
Distant metastasis
M1a Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion** Any T Any N M1b
Small cell lung cancer SWOG protocols in small cell lung cancer typically use extent of disease (limited versus extensive) to define stage groupings. These groupings are defined as follows:
Limited disease is confined to the single hemithorax, ipsilateral hilar lymph nodes, mediastinum, and/or ipsilateral supraclavicular lymph nodes. In addition, the patient's disease must be encompassable in a single radiation port.
Extensive disease is disease spread beyond the areas defined for limited disease. A patient with malignant pleural effusions is classified as having extensive disease.
